Publications
81
Citations
598
Est. group size
~1
Recurring co-author estimate
Active years
15
Publishing since 2012
This researcher works on cancer immunotherapy, focusing on how the immune system can be activated or redirected to attack tumors such as breast cancer and melanoma. Recent work explores drug combinations (like CDK4/6 inhibitors, STING agonists, and TLR4 agonists) paired with immune cell therapies (NK cells, dendritic cells) and nanoparticle-based delivery methods to boost the body's antitumor response. The work spans laboratory mouse models, patient-derived tumor samples, and early-stage drug/nanovaccine design.
Publication output was low and sporadic from 2017-2022 but increased sharply starting in 2023, peaking in 2024, suggesting a recent surge in research activity.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- CDK4/6 inhibition sensitizes breast cancer to NK cell therapy by inducing immune-interactive surface proteins
bioRxiv (Cold Spring Harbor Laboratory) · 2026
- Rare neuropsychiatric syndromes at the interface of neurology and psychiatry: a narrative review of diagnostic pitfalls and clinical lessons
Journal of Rare Diseases · 2026
- Potentiating cancer immunotherapies with modular albumin-hitchhiking nanobody–STING agonist conjugates
Nature Biomedical Engineering · 2025
- Macromolecular Diamidobenzimidazole Conjugates Can Activate Stimulator of Interferon Genes
Journal of the American Chemical Society · 2025
- Divergent paths of mammary gland involution: unveiling the cellular dynamics in abruptly and gradually involuted mouse models
Breast Cancer Research · 2025
- Macromolecular Diamidobenzimidazole Conjugates Activate STING
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- Artificial Intelligence Enhanced Mental Care Platform SAARTHI
2025
- A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists
ACS Nano · 2024
- TTK inhibitor OSU13 promotes immunotherapy responses by activating tumor STING
JCI Insight · 2024
- Programable Albumin-Hitchhiking Nanobodies Enhance the Delivery of STING Agonists to Potentiate Cancer Immunotherapy
Research Square · 2024
- Abstract 2138: Understanding the link between breastfeeding and the risk of breast cancer through comparative analysis of the murine-based model of mammary gland involution
Cancer Research · 2024
- Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses
Journal for ImmunoTherapy of Cancer · 2023
- Supplementary Figure S4 from Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition
2023
- Supplementary Figure S3 from Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition
2023
- Supplementary Figure S2 from Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition
2023
- Cell Reports×3
- bioRxiv (Cold Spring Harbor Laboratory)×3
- Cancer Research×3
- ACS Nano×1
- iScience×1
- Scott A. Hammond
Medicine · The Ohio State University
- Andrew J. Gunderson
Medicine · The Ohio State University
- Shreya Kumar
Medicine · Purdue University West Lafayette
- Richard C. Wu
Medicine · The Ohio State University
- Jonathan E. Schoenhals
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile